A Phase II Trial of Neoadjuvant Chemotherapy with Genexol   ( XXXX ) and @entity1259 for Locally Advanced @entity0 .

@entity1 @entity632 @entity137 @entity0 @entity66 @entity5 @entity1259 @entity1311 @entity1398 @entity74 @entity1370
PURPOSE: Neoadjuvant chemotherapy (NC) is yet to be established as the definitive treatment regimen for locally advanced @entity0 (LABC). The aim of this study was to determine the efficacy and @entity137 of NC with @entity1259 and @entity1311 . METHODS: Between March 2007 and January 2009, 50 @entity1 with LABC were enrolled in an open-label, phase II, multicenter study carried out at five distinct institutions. All @entity1 were scheduled to receive four cycles of 60 mg/m(2) @entity1259 and 175 mg/m(2) @entity1311 every 3 weeks, preoperatively, unless they developed profound side effects or disease progression. After curative surgery, two additional cycles of chemotherapy were administered to @entity1 who had shown a positive response to NC. RESULTS: In all, 196 cycles of chemotherapy were administered preoperatively; 47 of the 50 @entity1 (94%) underwent all four cycles of designated treatment. Complete disappearance of invasive foci of the @entity5 , and negative axillary lymph nodes were confirmed in eight @entity1 (16.0%), post operation. The cumulative 5-year disease-free survival rate was 70.0% for @entity1 with complete remission (CR) and partial remission (PR), and 33.3% for @entity1 with @entity66 ( @entity66 ) and @entity74 ( @entity74 ) (p=0.018). The cumulative 5-year overall survival was 90.0% for @entity1 who achieved CR and PR and 55.6% for @entity1 who had @entity66 and @entity74 (p=0.001). @entity1398 (42.0%) was the most common grade 3/4 @entity137 . However, none of the @entity137 resulted in cessation of the treatment. CONCLUSION: The encouraging pathologic response observed in the @entity1 treated with @entity1259 plus @entity1311 NC in this study suggests that @entity1259 could be a substitute for @entity632 , which is the most @entity1370 agent.
